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Abstract
Background: Thyroid abnormalities (hyperthyroid and hypothyroid) are accompanied by changes
in intermediary metabolism including alterations in body weight, insulin resistance and lipid profile.
The aims of this study were to examine plasma ASP, its precursor C3 and adiponectin in
hyperthyroid and hypothyroid subjects as compared to controls.
Methods:  A total of 99 subjects were recruited from endocrinology/out-patient clinics: 46
hyperthyroid subjects, 23 hypothyroid subjects and 30 control subjects. Subjects were evaluated
for FT4, FT3, TSH, glucose, insulin, complete lipid profile and the adipokines: adiponectin, acylation
stimulating protein (ASP) and complement C3.
Results: Hyperthyroidism was associated with a 95% increase in adiponectin (p = 0.0002), a 47%
decrease in C3 (p < 0.0001), no change in ASP and increased ASP/C3 ratio (p = 0.0012).
Hypothyroidism was associated with a 31% increase in ASP (p = 0.008). Adiponectin and C3
correlated with FT3 (r = 0.383, p = 0.004 and r = -0.277, p = 0.007, respectively) and FT4 (r =
0.464, p = 0.003 and r = -0.225, p = 0.03, respectively). ASP correlated with TSH (r = 0.202, p =
0.04). Adiponectin did not correlate with either ASP or C3, only ASP and C3 correlated (r = -0.197,
p = 0.05). Adiponectin was negatively correlated with BMI, total cholesterol and plasma
triglyceride, while C3 was positively correlated with BMI and total cholesterol. Surprisingly,
adiponectin was positively correlated with insulin (r = 0.293, p = 0.02) and HOMA-IR (r = 0.373, p
= 0.003) while C3 was negatively correlated with glucose (r = -0.242, p = 0.022, insulin (r = -0.184,
p = 0.05) and HOMA-IR.
Conclusion: These changes suggest that thyroid disease may be accompanied by changes in
adipokines, which may contribute to the phenotype expressed.
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Introduction
Thyroid abnormalities (hyperthyroid and hypothyroid)
are accompanied by changes in intermediary metabolism
including alterations in body weight, insulin resistance
and lipid profile (review [1,2]. Specifically, hyperthy-
roidism is characterized by decreased body weight,
increased insulin and glucose indicative of insulin resist-
ance as well as decreases in plasma lipids such as plasma
cholesterol and triglycerides. These changes are a conse-
quence of the cellular effect of thyroid hormone on liver,
muscle and adipose tissue metabolism, which leads to
increased energy expenditure. Conversely, hypothy-
roidism is associated with decreased levels of triiodothy-
ronine (T3), thyroxine (T4) and increased thyroid
stimulating hormone (TSH). These changes lead to
increased body weight with increased plasma lipids and
lipoproteins. Interestingly, plasma triglyceride, LDL cho-
lesterol and HDL cholesterol are all increased in hypothy-
roidism and decreased in hyperthyroidism [2,3],
disrupting the normal inverse relationship seen between
triglyceride and HDL cholesterol. As many of these
changes are associated with alterations in glucose and
insulin metabolism, and alterations in adipose tissue, we
were interested in assessing the effect on adipokine hor-
mones.
Adiponectin is a recently described adipose tissue hor-
mone with multiple functions (review [4]). Plasma adi-
ponectin has been reported to correlate with plasma
lipids, in particular HDL cholesterol (HDL-C) (positively)
[5,6], as well as to insulin resistance (negatively) with
decreased plasma levels often reported in type 2 diabetes
[7,8]. Interestingly, adiponectin, although produced in fat
tissue, decreases in obesity [4]. Functional studies suggest
that adiponectin administration can alter insulin sensitiv-
ity, but it can also mediate numerous anti-atherosclerotic
vascular functions such as endothelial function, inhibi-
tion of smooth muscle cell proliferation and inhibition of
macrophage conversion to foam cells (review [4]). Adi-
ponectin has been suggested to increase fatty acid oxida-
tion and alter energy expenditure [9,10], although this
function remains controversial [11].
In contrast to the proposed effects of adiponectin on
increasing energy expenditure, acylation stimulating pro-
tein (ASP) enhances energy storage through increasing
postprandial triglyceride clearance, adipose tissue fatty
acid esterification, glucose uptake and decreasing hor-
mone sensitive lipase mediated lipolysis (review [12]). In
a number of studies, ASP has been demonstrated to be
increased in obesity, diabetes and cardiovascular disease
(review [12]), and while not exclusively produced by adi-
pose tissue, ASP generation increases in the adipose tissue
milieu postprandially. Plasma ASP levels correlate posi-
tively with body mass index, as well as with plasma lipids
such as total cholesterol, LDL cholesterol and apolipopro-
tein B. ASP often correlates with non-esterified fatty acids
(NEFA)[12]. Interestingly, in C3(-/-) mice that are defi-
cient in ASP, there is a decrease in adipose tissue mass
with a repartitioning of ingested food towards increased
energy expenditure (review [12]).
ASP, identical to C3adesArg, is produced through the
alternate complement pathway via cleavage of comple-
ment C3, which is produced in multiple tissue sites,
including the liver and adipose tissue. The cleavage of C3
is initiated through the action of adipsin (complement
factor D), which, like adiponectin, is produced primarily
in adipose tissue [13,14]. Independent of its role in gener-
ation of ASP, C3 appears to have direct links to insulin
resistance and plasma lipids, an association that is specific
to this complement protein [15,16]. C3 is increased in
diabetes and in patients with coronary disease. C3 corre-
lates strongly with insulin resistance [12], and in a study
by Muscari et al, was shown to be a stronger predictor of
insulin resistance and myocardial infarction than tradi-
tional risk factors [15].
The aims of this study were to examine plasma ASP, its
precursor C3, and adiponectin in hyperthyroid and
hypothyroid subjects as compared to controls. We tested
(1) whether plasma ASP, C3 or adiponectin concentra-
tions are associated with thyroid status in patients and (2)
whether the levels of plasma C3 directly correlate with
concentrations of ASP across all groups.
Research design and methods
Subjects
A total of 99 subjects were recruited from endocrinology
and out-patient daily clinics at the Tongji Medical Centre,
Tongji Hospital, Wuhan, Hubei, P.R. China. Participants
ranged from 18 to 67 years old. All participants gave
informed consent and the study was approved by Tongji
Hospital Ethics Committee. Subjects with diabetes, liver
disease, heart disease, infectious disease or any other
known disease were excluded. All subjects were ambula-
tory and were studied as out-patients. No subjects were
taking any medication or herbal remedies known to affect
lipid metabolism. Control subjects were recruited during
their evaluation for a regular medical check-up. All con-
trol subjects were non-obese and had T3, T4 and TSH val-
ues within normal ranges (see below).
All thyroid patients were evaluated at the time of diagno-
sis during their initial visit to the Endocrinology Clinic.
Onset of symptoms was recent (within 2–3 months) and
no patients were taking any thyroid medication or herbal
remedies. Hyperthyroid subjects were primarily diag-
nosed with Graves disease, and presented with T3 and T4
above the normal ranges and TSH below the normal rangeNutrition & Metabolism 2006, 3:13 http://www.nutritionandmetabolism.com/content/3/1/13
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(see below for ranges). Hypothyroid subjects were diag-
nosed with auto-immune disease, with biochemical
parameters of T3 and T4 below normal ranges, and TSH
above the normal range.
Fasting blood samples and OGTT
Blood samples were drawn after an overnight fast from an
antecubital vein. Fasting plasma samples were used for
measurement of all parameters. Blood was centrifuged
and plasma aliquoted and frozen immediately for future
analysis of lipids and proteins.
Analytical procedures
Blood glucose was determined by glucose-oxidase
method (AVE-852 half-auto biochemical analyzer).
Plasma NEFA concentration was determined by colori-
metric enzymatic assay (WAKO Chemicals, Tokyo,
Japan). Plasma triglycerides were measured by GPO-PAP
method and total cholesterol was measured by COD-PAP
method. Following precipitation of apoB containing lipo-
proteins, the concentration of HDL-cholesterol (HDL-C)
was also measured by enzymatic colorimetric assay (BCR,
Ai-Weihali autobiochemical analyzer). Inter and intra
coefficient of variation (CV) for all parameters (except
HDL) were <3%. For HDL, inter and intra CV were <5%.
FT3 (free T3), FT4 (free T4) and TSH were measured by
automated chemiluminescence immunoassay (ACS-180,
American Kang Ning Company). The intra assay and inte-
rassay coefficient of variation were 2% and 6% respec-
tively, for both FT3 and FT4. The normal range within the
clinical biochemistry laboratory for T3 is 3.95–6.47 pmol/
L, for T4 the normal range is 11.99–21.00 pmol/L and for
TSH the normal range is 0.27–4.2 mU/L. Insulin was
measured by electrochemiluminescence immunoassay
(Elecsys 1010, Roche Instrument Center AG). Plasma adi-
ponectin concentration was measured by ELISA (B-Bridge
International, Phoenix, AZ, USA). Complement C3 was
measured by an immunoturbidimetric assay (Lin- Fei Co,
P.R. China). Plasma ASP concentration was measured via
a sandwich ELISA immunoassay as previously described
in detail [17,18]. For these last assays, (insulin, adiponec-
tin and ASP) intra-assay CV was <4% and interassay CV
was <8%.
Table 2: Fasting lipid profiles in subject groups
Parameter CTL HYPER HYPO ANOVA
N 3 04 62 3< 0 . 0 0 0 1
TG (mmol/L) 1.14 ± 0.12 0.73 ± 0.06**,††† 1.74 ± 0.09*** <0.0001
TChol (mmol/L) 4.58 ± 0.15 2.72 ± 0.14***,††† 6.16 ± 0.24*** <0.0001
LDL-C (mmol/L) 2.40 ± 0.16 1.41 ± 0.09***,††† 3.66 ± 0.18*** <0.0001
HDL-C (mmol/L) 1.56 ± 0.06 0.99 ± 0.04*** 1.74 ± 0.07††† <0.0001
NEFA (mmol/L) 0.361 ± 0.03 0.617 ± 0.05*** 0.425 ± 0.03††† <0.0001
Results are expressed as average ± SEM for the four groups indicated as control (CTL), hyperthyroid (HYPER) and hypothyroid (HYPO) where TG 
= plasma triglyceride, TChol = total cholesterol, LDL-C = LDL cholesterol, HDL-C = HDL cholesterol and NEFA = non-esterified fatty acids. 
Significance was calculated by ANOVA with Bonferroni post-hoc test where differences vs. control (CTL) group are indicated as *P < 0.05,**P < 
0.01,***P < 0.001; and differences between hyperthyroid and hypothyroid are indicated as †p < 0.05, ††p < 0.01, †††p < 0.001.
Table 1: Clinical and laboratory data in subject groups
Parameter CTL HYPER HYPO ANOVA
N3 0 4 6 2 3
Gender (M/F) 10/20 13/33 5/18 ns
Age (years) 41.7 ± 2.0 34.9 ± 1.6* 39.4 ± 2.5 0.029
BMI (kg/m2) 22.0 ± 0.4 21.2 ± 0.4††† 24.2 ± 0.61* 0.0003
Glucose (mmol/L) 4.88 ± 0.11 5.47 ± 0.07*** 5.08 ± 0.12† <0.0001
Insulin (pmol/L) 34.0 ± 5.5 60.8 ± 4.9*** 33.8 ± 2.8†† <0.0001
HOMA-IR 1.10 ± 0.20 1.86 ± 0.16** 1.02 ± 0.11†† 0.0004
FT4 (pmol/L) 17.4 ± 0.4 64.5 ± 8.4*** 9.1 ± 0.6*††† <0.0001
FT3 (pmol/L) 5.7 ± 0.1 13.3 ± 1.2*** 3.2 ± 0.2**††† <0.0001
TSH (mU/L) 2.1 ± 0.1 0.03 ± 0.02*** 69.5 ± 21.1**††† <0.0001
Results are expressed as average ± SEM for the groups indicated as control (CTL), hyperthyroid (HYPER) and hypothyroid (HYPO) where N = 
number of subjects per group. Significance was calculated by ANOVA with Bonferroni post-hoc test. Differences vs. control (CTL) group are 
indicated as *P < 0.05,**P < 0.01,***P < 0.001; and differences for hyperthyroid vs. hypothyroid as †p < 0.05, ††p < 0.01, †††p < 0.001, ns = not 
significant.Nutrition & Metabolism 2006, 3:13 http://www.nutritionandmetabolism.com/content/3/1/13
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Calculations
Body mass index (BMI) was calculated as weight (kg) per
height (m2). Insulin resistance index was calculated by
homeostasis model assessment, HOMA-IR, as (fasting
insulin IU/L) * (fasting glucose mmol/L) / 22.5 as previ-
ously reported by Matthews [19]. LDL cholesterol (LDL-
C) was calculated according to the Friedewald formula as
LDL-C = (total cholesterol mmol/L) – (triglyceride mmol/
L)/2.2 – (HDL-C mmol/L) [20].
Statistical analyses
Unless otherwise stated, data are given as means ± stand-
ard error of the mean (SEM). Statistical comparisons of
among all groups were performed using one-way ANOVA
analyses. Correlations were analyzed with Pearson corre-
lation coefficient or forward stepwise multiple regression
analysis where P <0.05 was considered to be statistically
significant for all analyses.
Results
A total of 99 subjects were recruited: 46 hyperthyroid
patients (13 men, 33 women), 23 hypothyroid patients (5
men, 18 women) and 30 control subjects (10 men, 20
women). Samples were taken at the time of the first visit
to the out-patient/endocrinology clinic. Patients were
excluded if they had heart disease, liver disease, diabetes
or any other known disease including infectious disease.
No subjects were taking any thyroid medication or any
medication known to affect lipids or hormone levels
(including any Chinese medicinal herbal preparations).
Control subjects were healthy and non-obese, and all had
normal levels of T3, T4 and TSH. Thyroid patients typi-
cally complained of palpitations, warmth and weight loss
(hyperthyroidism) or cold sensitivity, fatigue and lethargy
(hypothyroidism) but were generally healthy overall (see
Methods for detailed information on hyperthyroid and
hypothyroid classification). Onset of disease was recent
(within 2–3 months). The clinical laboratory data are pro-
vided in Table 1. As shown in Table 1, the hyperthyroid
(HYPER) group was slightly younger than the control
group (CTL), but with similar body mass index (BMI). The
hypothyroid (HYPO) group was matched for age, but had
an increased BMI compared to the CTL group. Hyperthy-
roid subjects were characterized by increased fasting
plasma glucose, insulin and HOMA-IR. As expected,
based on diagnosis of hyperthyroidism, FT3 and FT4 were
above normal, while TSH was below normal (vs. control
subjects as indicated in Table 1). By contrast, in the HYPO
group, glucose, insulin and HOMA-IR were comparable to
CTL, but different from the hyperthyroid group. As
expected, FT4 and FT3 were below normal, with a raised
TSH level.
Fasting lipid profiles are shown in Table 2. In the HYPER
group, plasma triglycerides, total cholesterol, LDL choles-
terol and HDL cholesterol were all strikingly reduced
compared to the CTL group, whereas NEFA concentra-
tions were substantially increased. By contrast, in the
HYPO group, plasma triglycerides, total cholesterol and
LDL cholesterol were all substantially increased compared
to CTL.
The results for adipose tissue hormones are shown in Fig-
ure 1. In the HYPER group, adiponectin was substantially
increased by 95% as compared to CTL group (p = 0.0002
by ANOVA), while C3 was decreased by 47% (p < 0.0001
by ANOVA). Similar differences were obtained for adi-
ponectin when separated into male and female groups
(not shown). In spite of the substantial reduction in C3,
the precursor to ASP, ASP levels remained normal, there-
fore the %ASP/C3 ratio increased by 64% (p = 0.0012 by
ANOVA). By contrast, in the HYPO group, there was no
significant change in either adiponectin or C3 compared
to CTL, but there was an increase in ASP of 31% (p = 0.008
by ANOVA).
As shown in Table 3, all three adipose tissue hormones
and insulin correlated significantly with indices of thyroid
function. Specifically, adiponectin and C3 correlated with
FT3 (r = 0.382, p = 0.002 and r = -0.278, p = 0.007, respec-
tively) and FT4 (r = 0.464, p = 0.0001 and r = -0.225, p =
0.03, respectively). Insulin also correlated with both FT3
and FT4 (r = 0.389, p = 0.003 and r = 0.395, p = 0.003,
respectively). ASP correlated with TSH (r = 0.202, p =
0.04). Adiponectin did not correlate with either ASP or
C3, only ASP and C3 correlated (r = -0.197, p = 0.05).
Further both C3 and adiponectin correlated with a
number of plasma parameters. Adiponectin was nega-
tively correlated with BMI, total cholesterol and plasma
triglyceride, while C3 was positively correlated with BMI
and total cholesterol. Surprisingly, adiponectin was posi-
tively correlated with insulin and HOMA-IR, while C3 was
negatively correlated with glucose, insulin and HOMA-IR.
In best subset regression analysis, adiponectin was best
predicted by a combination of: FT4 (p = 0.001) + HOMA-
IR (p = 0.05) + TChol + HDL-C + LDL-C (p = 0.05) (r2 =
0.368, p = 0.001). Obligatory inclusion of BMI did not
improve the correlation. C3 was best predicted by a com-
bination of ASP, NEFA and HDL (r2 = 0.369 where ASP p
= 0.012, NEFA p = 0.031 and HDL-C p = 0.042). Obliga-
tory inclusion of BMI did not improve the correlation.
Finally, ASP was best predicted by a combination of TSH,
C3, NEFA, BMI, TChol, HDL-C and LDL-C (r2 = 0.240,
with the following individual p values: TSH (0.012), C3
(0.018), BMI (0.050), TChol (0.048), HDL-C (0.063).
Discussion
The salient findings in the present study are the associa-
tion of hyperthyroidism with increased adiponectin,Nutrition & Metabolism 2006, 3:13 http://www.nutritionandmetabolism.com/content/3/1/13
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decreased C3 and increased ASP/C3 ratio, and of hypothy-
roidism with increased ASP. Further, these changes in adi-
pokines are each associated with specific changes in
glucose or lipid metabolism which reflect whole body
changes in energy expenditure/energy storage as discussed
below. Thus this study provides important new data in
this area.
With respect to adiponectin, the increased levels in hyper-
thyroidism are consistent with the increased metabolic
rate that is characteristic of these patients. Our results con-
trast with those of Iglesias [21], where no significant
changes were found. However it is difficult to draw con-
clusions since the average levels of adiponectin in that
study were greater in all groups with a large range in values
obtained (based on reported s.e.m.), the immunoassays
used were different from the present study, and the age of
the subjects was older. A study by Santini et al also exam-
ined adiponectin in hyperthyroid/hypothyroid subjects
and found no significant differences. However the subject
size was small, and this may have confounded the data
(the authors suggest this to explain the lack of correlation
in their study between adiponectin and BMI) [22]. In con-
trast with these two studies, Yaturu and colleagues did
find that adiponectin levels were higher in the hyperthy-
roid state than in the hypothyroid state, in agreement with
our study [23]. Further, a study of 68 healthy subjects
demonstrated a positive association between plasma adi-
ponectin and thyroid hormones although hyperthyroid
and hypothyroid subjects were not tested directly [24].
Interestingly, in our study, the hyperthyroid subjects are
also insulin resistant, with increased insulin levels. While
insulin resistance is usually associated with decreased adi-
Adipocyte hormones in control (CTL), hyperthyroid (HYPER) and hypothyroid (HYPO) subjects Figure 1
Adipocyte hormones in control (CTL), hyperthyroid (HYPER) and hypothyroid (HYPO) subjects. Results are 
expressed as average ± SEM for the three groups indicated. Significance was calculated by ANOVA for all groups with Bonfer-
roni post-hoc test where differences vs. control (CTL) group are indicated as *P < 0.01,***P < 0.001; and differences for HYPO 
vs. HYPER indicated as +p < 0.05 and ++ p < 0.01.
CTL HYPER HYPO
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ponectin levels, at least in diabetics [4,7,8], in hyperthy-
roidism this inverse relationship appears to be lost, and
there is a direct correlation of adiponectin with plasma
insulin and HOMA-IR. This is also true of the adiponectin
association with plasma lipids. While several studies in
controls, diabetic subjects and patients with cardiovascu-
lar disease have demonstrated a positive correlation of
adiponectin with HDL-C [5,6,25-30], this is not true in
the hyper/hypo thyroid subjects. In fact adiponectin cor-
relates inversely with total plasma cholesterol and triglyc-
erides but not HDL-C. This likely relates to the disruption
of the usual elevated triglyceride/low HDL cholesterol
relationship, which is a feature of hyper/hypothyroidism
[2,3]. This association of increased adiponectin with
decreased plasma lipids but increased NEFA is consistent
with an implication of adiponectin in fatty acid metabo-
lism. Enhanced release of NEFA from adipose stores, cou-
pled to increased adiponectin may stimulate fatty acid
oxidation in muscle and liver [9] with a comparable
decrease in lipoprotein production [10]. The result is an
anti-atherogenic lipid profile, which may be mediated
through both thyroid hormones as well as adiponectin.
This raises some interesting questions/hypotheses as to
the mechanism of increased adiponectin secretion from
adipocytes in hyperthyroid subjects. Evidence for a role of
thyroid hormones in the regulation of adiponectin expres-
sion is suggested in a recent study showing increased adi-
ponectin in mice exposed to cold [31]. On the other hand,
insulin has also been reported to stimulate adiponectin
secretion [32-34], and the increased levels in the hyper-
thyroid subjects may also act as a stimulus. These hypoth-
eses, however, remain to be tested experimentally.
In contrast to adiponectin, C3 was markedly decreased in
hyperthyroid subjects, while ASP was increased in
hypothyroid patients as compared to CTL. Directionally,
the differences between hyper- and hypo- thyroid patients
were the same for ASP and its precursor C3, in that both
C3 and ASP were greater in hypothyroid than in hyperthy-
roid. However, the correlation of C3 with lipid and glu-
cose parameters was stronger than the correlations with
ASP. Other than the requirement of C3 as precursor for
ASP, there is no known role for C3 in glucose or lipid
metabolism, notwithstanding the many studies that have
documented correlations of C3 with glucose and lipid
metabolism and insulin resistance (review [12]. This
raises the question: Is there a direct effect of thyroid hor-
mones on C3 production? Thyroid hormones bind to
TREs (thyroid response elements), which heterodimerize
with RAR and RXR (retinoic acid response elements)
[35,36], the latter of which is known to regulate C3
expression [37], explaining the close correlation with C3.
Alternately, do the changes in thyroid hormones increase
C3 conversion to ASP or ASP clearance rates? How thyroid
hormones affect this process remains to be seen.
While this is the first report of ASP in hypothyroidism, the
increased plasma levels of ASP are certainly consistent
with the increased BMI and lipids. As detailed elsewhere
(review [12], increased ASP is associated with obesity, dia-
betes and increased fasting plasma cholesterol, triglycer-
ide, apolipoprotein B and NEFA. Further, in oral fat load
studies, a higher ASP is associated with both increased
fasting triglyceride and a delay in triglyceride clearance,
suggesting ASP resistance [38]. While we can only specu-
late, this may also be true of hypothyroid subjects. True to
its proposed metabolic function, the increased plasma
ASP levels are indicative of a push towards NEFA storage
rather than oxidation, towards decreased energy metabo-
lism, and towards an increase rather than a decrease in
BMI. Interestingly in this setting of increased lipids but
normal glucose, only ASP is increased while insulin
remains at normal levels. These results dovetail with the
studies on C3(-/-) ASP deficient mice, which are deficient
Table 3: Correlations between thyroid hormones, adipokines and plasma parameters
Parameter Adiponectin ASP C3 %ASP/C3 Insulin
r/(P) r/(P) r/(P) r/P r/(P)
FT3 0.382(.002) -.022(.831) -0.278(.007) 0.222(.030) 0.389(.003)
FT4 0.464(.0001) 0.020(.851) -0.225(.03) 0.147(.158) 0.395(.003)
TSH -0.080(.538) 0.202(.04) 0.121(.252) -0.022(.834) -0.071(.497)
BMI -0.220(.05) -0.07(.445) 0.186(.05) -0.181(.05) -0.047(.653)
Glucose 0.230(.07) -0.022(.836) -0.242(.022) 0.273(.009) 0.250(.018)
Insulin 0.293(.02) 0.114(.273) -0.184(.05) 0.175(.05) ----------
HOMA-IR 0.373(.003) 0.132(.224) -0.184(.05) 0.174(.103) ----------
TChol -0.270(.032) 0.105(.307) 0.330(.001) -0.233(.022) -0.253(.013)
TG -0.319(.012) 0.108(.291) 0.162(.123) -0.104(.320) -0.061(.561)
HDL-C -0.147(.249) 0.035(.731) 0.417(.00002) -0.350(.00005) -0.115(.265)
LDL-C -0.195(.128) 0.099(.336) 0.291(.004) -0.218(.034) -0.287(.004)
NEFA 0.110(.397) 0.015(.885) -0.251(.015) 0.225(.028) 0.029(.776)
Results are provided for correlations (with P values indicated) for the whole cohort of subjects where BMI = body mass index, TChol = total 
cholesterol, TG = plasma triglyceride, NEFA = non-esterified fatty acid. Correlations which are significant are underlined.Nutrition & Metabolism 2006, 3:13 http://www.nutritionandmetabolism.com/content/3/1/13
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in ASP and manifest increased energy expenditure with
decreased body fat [39-41], while in the present subjects a
decrease in energy expenditure coupled with an increase
in BMI are associated with increased plasma ASP.
While, as noted above, there is no information available
on the direct effects of thyroid hormones on adiponectin,
ASP or C3 synthesis or secretion, there is additional infor-
mation on other cytokines in thyroid dysfunction. IL-6
and TNFα are both increased in Grave's disease (hyperthy-
roid state) [42,43], however since these cytokines have
been reported to decrease adiponectin [44] and increase
C3 [45], this cannot explain the demonstrated increase in
adiponectin and decrease in C3 in the hyperthyroid state
in the present study. However there is no lack of informa-
tion on the thyroid hormone mediated effects on adipose
tissue in vitro and in vivo. Thyroid hormone increases adi-
pose tissue lipolysis as measured by increased NEFA or
glycerol release [46-48] and increased β adrenergic
response [49-51]. Contrasting with the push for lipolysis,
hyperthyroidism induces down regulation of adipose
fatty acid synthase and lipoprotein lipase; most of these
effects reversed in hypothyroidism [52-54].
In summary, adipokines likely play an important role in
mediating energy partitioning towards either utilization
or storage. In that respect, ASP and adiponectin appear to
have opposite metabolic effects. In hyperthyroid subjects,
adiponectin is increased in a state where there is increased
fatty acid oxidation, whereas in hypothyroidism ASP is
increased where there is a push towards energy storage.
Thus the well documented effects of thyroid hormone
stimulation of energy expenditure in human and animal
studies may partly be achieved through enabling effects
on adipokines.
Abbreviations
ASP: acylation stimulating protein; BMI: body mass index;
C3: complement C3; HDL-C: high density lipoprotein
cholesterol; HOMA-IR: homeostasis model assessment of
insulin resistance; LDL-C: low density lipoprotein choles-
terol; NEFA: non-esterified fatty acids; PPARγ: peroxisome
proliferator-activated receptor γ; TG: triglyceride.
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